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Osteopetrosis is usually regarded as the disease of nonfunctioning osteoclasts, with a consequent
accumulation of osseocartilaginous material in the bone marrow. A recent report shows that, in
some patients with the rare autosomal recessive form of the disease, the osteoclast defect may be
non-cell autonomous, in this case due to a mutation in RANKL, the protein that normally controls
osteoclast formation and activity.Osteopetrosis is caused by a failure of
osteoclasts to resorb bone tissue re-
sulting in bone marrow cavities be-
coming occluded. This disease has
always fascinated bone cell biologists.
Although rare in humans, cases of os-
teopetrosis provide significant insight
into osteoclast biology. Osteopetrosis
is a monogenetic disease and, when-
ever it occurs, can be traced to a
gene essential to osteoclast function.
Although the molecular mechanisms
for most human forms of the disease
still remain unclear, this is not the
case in rodents. Genetic mouse
models have provided myriad exam-
ples of osteopetrosis, in part because
the bone phenotype is relatively easy
to discern. The diagnosis is character-
ized by failure of incisor teeth to form,
which leads to impaired food intake
and decreased body weight, and is
thus easy to recognize in early postna-
tal life. The condition is then confirmed
by radiography and morphology.
The importance of rodent models of
osteopetrosis has been recognized
since the mid-1970s with the indepen-
dent work of Donald Walker and John
Loutit, when the major question in the
field was the cellular origin of the oste-
oclast. Their pioneering work, using
transplantation and parabiosis in ro-
dents, showed that the osteoclast
was a circulating cell originating from
a spleen/bone marrow precursor (Lou-
tit and Nisbet, 1982; Walker, 1975).
This was a striking finding at that time
that refuted a popular notion that oste-
oclasts and osteoblasts were cells of
the same lineage. It also led to the first
case of human osteopetrosis success-
fully treated by bone marrow trans-
plantation several years later (Cocciaet al., 1980). However, transplantation
of osteoclast precursors is not always
successful, such as in cases of osteo-
petrosis where the defect is not intrin-
sic to these cells (Sobacchi et al.,
2007).
The past 20 years have seen a num-
ber of breakthroughs in our under-
standing of osteoclast biology gar-
nered from osteopetrotic research.
These have included identification of
the osteoclast vacuolar ATPase proton
pump (Sly et al., 1985), identification
of a mutation in the M-CSF receptor,
c-fms, in the op/op mutant (Felix
et al., 1990), and the unexpected find-
ing that a null mutation of c-src causes
a form of osteopetrosis in which oste-
oclasts are formed but are nonfunc-
tional (Lowe et al., 1993). The number
of murine variants of osteopetrosis
has grown in the past decade, and
we are developing a better under-
standing of the human disease, as
exemplified in a recent study by
Sobacchi et al. (2007).
The most severe form of human os-
teopetrosis is the malignant, infantile,
autosomal recessive variant (ARO).
ARO occurs because of specific muta-
tions in genes responsible for osteo-
clast function. Despite a decrease in
resorption, osteoclast numbers in the
majority of ARO patients are normal
or increased. These ‘‘osteoclast-rich’’
cases suggest that the osteoclast
defect does not affect osteoclast for-
mation but rather lies in their mature
functional capacity. Such mutations
include TCIRG1 and CLCN7, encod-
ing vital domains of the osteoclast-
specific vacuolar proton pump and
chloride ion channel, respectively (Fig-
ure 1). These mutations result in fullyCell Metabolism 6,differentiated, mature osteoclasts
that lack the capacity to acidify the
extracellular resorption space, a pre-
requisite for the dissolution of bone
mineral (Frattini et al., 2000; Kornak
et al., 2001).
In contrast, Sobacchi et al. (2007)
describe examples of ARO in which
osteoclasts were difficult to find (os-
teoclast-deplete or -poor). As noted
above and shown initially by Walker,
osteopetrosis is often treated suc-
cessfully by replacement of potentially
defective osteoclast precursors by he-
matopoietic stem cell transplantation
(HSCT). However, several subjects
studied in this report failed to improve
after HSCT. This strongly suggests
that healthy marrow cells could not
overcome the absence of osteoclasto-
genic stimuli and form healthy resorb-
ing mature osteoclasts within the
bone environment and indicates that
cells of the myeloid-monocytic line-
age, the osteoclast-precursor popula-
tion, are not the primary cell source of
this particular genetic defect. The au-
thors showed that circulating periph-
eral blood mononuclear cells from the
osteoclast-poor ARO subjects could
form osteoclasts possessing a number
of the defining characteristics of nor-
mal mature resorbing cells when cul-
tured in the presence of exogenous
RANKL. RANKL is required for normal
osteoclast formation and binds to its
receptor RANK on the surface of oste-
oclast precursors, leading to a cas-
cade of intracellular signaling proteins
that trigger the formation and sus-
tained activity of mature bone-resorb-
ing osteoclasts (Figure 1). The RANKL
protein is expressed by a variety of
cells in the bone marrow, includingSeptember 2007 ª2007 Elsevier Inc. 157
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PreviewsFigure 1. Mutations Linked to Osteopetrosis
A stylized depiction of the osteoclast lineage from multipotential progenitors to the mature multinucleated bone matrix (gray area) resorbing cell is
illustrated. Osteopetrosis occurs when there is a defect in osteoclast formation or activity. This may be due to a mutation in an essential gene in
the mature osteoclast or in its precursors. Examples of such mutations are shown alongside the progenitor cells. Osteopetrosis may also be due
to mutations in osteoclastogenic stimuli, such as RANKL, as described in the report by Sobacchi et al. (2007).osteoblasts, fibroblasts, and T cells, all
of which have been shown to regulate
osteoclast formation. Three out of the
six ARO subjects studied by Sobacchi
and colleagues displayed mutations in
the RANKL gene, which led to the for-
mation of truncated RANKL protein
missing vital structural and regulatory
domains. It should be noted that three
other subjects also had osteoclast-
poor osteopetrosis, but it could not
be attributed to a mutation in RANKL;
the molecular basis in these latter sub-
jects is currently unexplained. It is also
interesting to note that these human
cases differ from the corresponding
mice as the latter have immunologic
abnormalities not seen in the patients
(Kong et al., 1999).
Despite our current knowledge of
the molecular mechanisms respon-
sible for osteoclastogenesis and po-
tential insights into therapeutic ap-
proaches, a number of important
issues remain to be addressed in the
field. For a start, we do not have con-
sistent morphologic criteria for the di-
agnosis of osteopetrosis and do not158 Cell Metabolism 6, September 2007have a definition of the condition that
everyone agrees upon. Although it is
basically a morphologic diagnosis,
there are no generally accepted spe-
cific criteria. There are many examples
of confusion resulting from this. Is
pyknodysostosis the same disease
as osteopetrosis? Is bisphosphonate-
induced ‘‘osteopetrosis’’ really a form
of osteopetrosis? Why are there dis-
crepancies between human and mu-
rine forms of the disease caused by
the same gene defect? What is the
explanation for the formation of bone
in osteopetrosis, and why does osseo-
cartilaginous material accumulate?
Why is it that some of the animal
models resolve with age?
Notwithstanding these uncertainties
in the field, Sobacchi et al. (2007) have
added another important piece to our
understanding of this disease and its
underlying pathogenetic mechanisms.
Studies characterizing molecular de-
fects in previously untreatable dis-
eases are particularly powerful when
they point to feasible therapies that
may reverse the abnormality, whichª2007 Elsevier Inc.seems likely in this case. The bone
field eagerly awaits the first reports of
trials with RANKL in patients who
have normal osteoclasts and cannot
be cured by HSCT.
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Chemerin is a newly described a
in vitro. Its relationship with bod
larger role for this protein in obes
Adipose tissue biology has drawn
much attention over the last several
years, due in part to the increasing in-
cidence of obesity and associated
metabolic disorders and the hope
that understanding the biology of fat
will translate into a cure for bulging
waistlines. Adipose tissue is recog-
nized as an organ that not only stores
energy but also acts as a multifunc-
tional endocrine tissue. Adipocytes
produce hormones (termed adipo-
kines) that regulate systemic pro-
cesses, including food intake and nu-
trient metabolism, insulin sensitivity,
stress responses, reproduction, bone
growth, and inflammation. A growing
number of reports describe proteins
that are secreted from adipocytes
or preadipocytes. While leptin has
systemic effects on appetite and me-
tabolism and is undoubtedly the most
studied secreted adipocyte protein,
endocrine functions have been de-
scribed formultipleadipokines. Inaddi-
tion, autocrine/paracrine factors from
adipocytes influence adipose develop-
ment and metabolism, vascularization,
and recruitment of inflammatory cells.
Two recent publications now add
chemerin (aka RARRES2 or TIG2;
Bozaoglu et al., 2007; Goralski et al.,
2007) to the growing list of secreted
adipocyte proteins. The data indicateSly, W.S., Whyte, M.P., Sundaram, V.,
Tashian, R.E., Hewett-Emmett, D.,
Guibaud, P., Vainsel, M., Baluarte, H.J.,
Gruskin, A., Al-Mosawi, M., et al.
(1985). N. Engl. J. Med. 313, 139–
145.nding Family of A
les F. Burant1,*
Physiology and Internal Medicine, Universit
(O.A.M.), burantc@umich.edu (C.F.B.)
dipokine with effects on adipocyt
y mass index and aspects of the
ity-associated complications.
that chemerin has local effects on
adipogenesis and perhaps wider ef-
fects on metabolism and inflammation
(Figure 1).
Chemerin is a secreted chemoat-
tractant protein of 16 kDa, synthe-
sized as prochemerin and activated
through serine protease C-terminal
cleavage triggered as part of host
survival defense (i.e., complement,
fibrinolysis, coagulation, and from leu-
kocyte granules) (Wittamer et al.,
2003). Initially purified from biological
fluids associated with inflammation
(ovarian cancer ascites and rheuma-
toid arthritis synovial fluids), high levels
of mRNA in adipose tissue suggest
a role for chemerin in adipocyte biology
(Bozaoglu et al., 2007; Goralski et al.,
2007). Chemerin is expressed at very
low levels in 3T3-L1 preadipocytes,
but expression and secretion increase
dramatically during adipogenesis
in vitro (Bozaoglu et al., 2007; Goralski
et al., 2007). Adipocytes purified from
adipose tissue contain high levels of
chemerin mRNA; however, substantial
expression in stromal vascular cells
suggests that production from nonadi-
pocytes may also be important (Goral-
ski et al., 2007). Chemerin mRNA
expression is not altered in white adi-
pose tissues of genetically obese ob/
ob mice compared to lean controls,
Cell Metabolism 6, SSobacchi, C., Frattini, A., Guerrini, M.M., Abi-
nun, M., Pangrazio, A., Susani, L., Bredius,
R., Mancini, G., Cant, A., Bishop, N., et al.
(2007). Nat. Genet. 39, 960–962.
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y of Michigan Medical School,
e differentiation and metabolism
metabolic syndrome suggests a
but it is increased in subcutaneous adi-
pose tissue of fat sand rats (P. obesus,
whichare actually gerbils)with impaired
glucose tolerance. Chemerin is also
elevated in all adipose tissue depots
in diabetic P. obesus relative to eugly-
cemic lean controls (Bozaoglu et al.,
2007). However, there was no change
in expression in the stromal-vascular
fraction with impaired glucose toler-
anceordiabetes. Inhumans, circulating
levels of chemerin correlate with body
mass index, plasma triacylglycerol
concentrations, and blood pressure
but are not altered by the presence of
type 2 diabetes (Bozaoglu et al., 2007);




G protein-coupled receptor (GPCR),
chemokine like receptor-1 (CMKLR1).
Expression of this receptor had been
demonstrated in circulating plasmacy-
toid dendritic cells and tissue-resident
macrophages. The new work shows
that, like chemerin, CMKLR1 is highly
expressed in adipose tissues, with
slightly higher expression in adipocytes
compared to stromal vascular cells.
While Goralski et al. observed striking
induction of CMKLR1 expression dur-
ing 3T3-L1 adipogenesis, Bozaoglu
et al. observed repression of this gene
eptember 2007 ª2007 Elsevier Inc. 159
